• Most Popular
  • Most Shared

REUTERS SHOWCASE

New Antibiotics

New Antibiotics

U.S. government taps GlaxoSmithKline for new antibiotics  Full Article 

Medical Marijuana

Medical Marijuana

Los Angeles voters OK move to curtail medical marijuana outlets  Full Article 

Birdflu Cost

Birdflu Cost

China's bird flu outbreak cost $6.5 billion  Full Article 

Group Workouts

Group Workouts

Putting group fitness classes in the proper light  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Neurosearch denies share manipulation charges

Related Topics

Stocks

   

COPENHAGEN | Wed May 23, 2012 3:24pm IST

COPENHAGEN (Reuters) - Danish biopharma firm Neurosearch A/S said on Wednesday charges of share price manipulation had been filed against it, but it denied the allegations and said it was working with the authorities to clear up the matter.

Neurosearch said the charges were related to an announcement in February 2010 in which the management of the company reported top-line results from a Phase III study with its Huntington's disease drug candidate Huntexil and then two months later reassessed and corrected the data in a new announcement.

"On the present basis, Neurosearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter," the company said in a statement.

(Reporting by John Acher)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.